Unique population of regulatory t cells that regulate tissue regeneration and wound healing
AssigneePresident and Fellows of Harvard College
InventorsDiane Mathis, Christophe Benoist, Dalia Burzyn, Amy Wagers
Life of this patent
Estimating the term…
Abstract
A unique type of regulatory T cell has been identified in muscle. These tissue-regenerative Treg cells play a role in regulating wound healing. These cells, as well as agents that control their differentiation and/or activity and agents produced by the cells, can be used to modulate wound healing and the differentiation of muscle cells.
Claims31
A composition of Foxp3+CD4+ regulatory T (Treg) cells isolated from muscle, which Treg cells exhibit tissue-regenerative properties, wherein the Treg cells are characterized by transcription of IL10, Pcsk1, Areg, Pcyt1a, Frmd5, Ccr1, Ccr3, Lyn, Arnt2, Pparg, Ctsh, Havcr2(TIM3), Gpr55, Il23r, Itgae, Ccr6, Dgat2, Rorc, CD74, Il1r2, Il1r11 (ST2), CD200r1 and Trf at levels higher than splenic, lymph node Treg cells, or conventional T cells.
(canceled)
5-6. (canceled)
(canceled)
11-12. (canceled)
A method of producing a population of cells enriched for tissue regenerative Treg cells, the method comprising obtaining a starting population of cells comprising FoxP3+ CD4+ Treg cells and selecting or inducing cells from the starting population that express IL10, Pcsk1, Areg, Pcyt1a, Frmd5, Ccr1, Ccr3, Lyn, Arnt2, Pparg, Ctsh, Havcr2(TIM3), Gpr55, Il23r, Itgae, Ccr6, Dgat2, Rorc, CD74, Il1r2, Il1r11 (ST2), CD200r1 and Trf at levels higher than the bulk populations of splenic or lymph node circulating Treg cells and conventional T cells for all sites, to thereby produce a population of cells enriched for tissue regenerative Treg cells.
A method of promoting wound healing comprising contacting muscle cells of a subject in need of wound healing with at least one agent that promotes the development of Treg cells, wherein the at least one agent is selected from the group consisting of:
- anti-CD3, at least one PPARγ agonist, at least one thiazolidinedione-like drug, an IL-2/anti-IL-2 complex, and pioglitazone.
25-26. (canceled)
A method of promoting wound healing comprising contacting muscle cells of a subject in need of wound healing with an agent derived from tissue regenerative Treg cells.
The method of claim 26, wherein the agent is selected from the group consisting of:
- IL-10, Areg (amphiregulin), Havcr2 (TIM3) and Npnt (nephronectin).
(canceled)
31-33. (canceled)
(canceled)
Dependencies are inferred from the claim text.